first-in-class oral MAT2A allosteric inhibitor

synthetic lethal candidate in Ph. I for MTAP-

from >2000 fragment library and SBDD

J. Med. Chem., Apr. 8, 2021

Agios Pharmaceuticals, Cambridge, MA

AG-270

The Agios first-in-class oral MAT2A enzyme allosteric inhibitor, AG-270, is a Ph. I clinical candidate for tumors with MTAP gene loss. The inhibitor works on a synthetic lethality principle: the MTAP-loss which drives…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: